Charles Payne put a "screaming buy" on GNBT..
biz.yahoo.com
wstreet.com
Noted Wall Street Analyst Highlights Generex Biotechnology in Report
Thursday November 15, 10:38 am ET
WORCESTER, Mass., Nov. 15, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (NasdaqCM:GNBT - News), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that Charles V. Payne and Wall Street Strategies, an independent stock market research company, have published a report on the Company. Mr. Payne is the Chief Analyst at Wall Street Strategies, and is a frequent guest on several well-respected finance-oriented radio and television programs and is widely recognized in the media as a leader in the analyst community. He is routinely sought after for his market opinions by several prestigious news organizations.
According to the report, ``Less than two weeks ago, the company received approval for its delivery system, Oral-lyn in India, and the news sent the shares significantly higher. Since then, the stock has drifted lower and in our estimation makes it a screaming buy.''
The report also noted that, ``Management has so much passion in their fight against diabetes, bird flu, AIDS, and cancer that they haven't paid a lot of attention to the stock. Currently, Oral-lyn is in phase III testing in North America. We expect that approval would automatically make this a $5.00 stock, but once sales begin we think the stock could move even higher.''
The entire report is available at wstreet.com |
